title: CD19: A multifunctional immunological target molecule and its implications for Blineage acute lymphoblastic leukemia.
abstract: Over the last 20-30 years CD19 has gained attention as a potential target in the therapy of B-cell malignancies. In particular, targeting CD19 with the bispecific T-cell engager (BiTE) antibody Blinatumomab and T-cells modified by chimeric antigen receptors (CAR) has shown promising efficacy in early phase clinical trials for adults and children with precursor B-cell ALL (BCP-ALL). This review will discuss the rationale behind targeting CD19 in BCP-ALL and its potential importance in BCP-ALL signaling pathways.
authors.affiliation: Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, UK.|Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
authors.forename: Judith
authors.initials: J
authors.lastname: Weiland
authors.affiliation: Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, UK.
authors.forename: Alex
authors.initials: A
authors.lastname: Elder
authors.affiliation: Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, UK.
authors.forename: Victoria
authors.initials: V
authors.lastname: Forster
authors.affiliation: Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, UK.
authors.forename: Olaf
authors.initials: O
authors.lastname: Heidenreich
authors.affiliation: Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
authors.forename: Steffen
authors.initials: S
authors.lastname: Koschmieder
authors.affiliation: Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, UK.|Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
authors.forename: Josef
authors.initials: J
authors.lastname: Vormoor
mesh_terms: D000328:Adult; D018033:Antibodies, Bispecific / Q000494:pharmacology*; D018941:Antigens, CD19 / Q000737:chemistry / Q000276:immunology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D006801:Humans; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000276:immunology
chemical_list: D018033:Antibodies, Bispecific; D018941:Antigens, CD19; D000970:Antineoplastic Agents; C510808:blinatumomab
keywords: BCP-ALL; CD19; blinatumomab; childhood leukemia; pre-BCR